In this newly created position, Bi will oversee development of technical data and information to support the use of ISP’s solubility enhancing ingredient portfolio and solid dispersion development services by pharmaceutical formulators.
With experience in oral drug delivery systems formulated for bioavailability enhancement, Bi is author of more than 40 research papers and abstracts in formulation research. Prior to joining ISP, she was associate principal scientist at AstraZeneca Pharmaceuticals.
‘ISP is pleased to appoint a scientist with experience in confronting the challenges in developing poorly soluble drugs to lead this important R&D initiative,’ said Philip Strenger, senior vice president, Global Pharmaceuticals at ISP.
‘Dr Bi knows the processes pharmaceutical makers follow when formulating poorly soluble entities and the general pathways pharmaceutical makers follow when commercialising such entities. We are confident Dr Bi will be an asset to companies that want to reduce the development timeline and costs associated with the development of poorly soluble drugs.’
